L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation

Alain G. Zeimet, Daniel Reimer, Monica Huszar, Boris Winterhoff, Ulla Puistola, Samira Abdel Azim, Elisabeth Müller-Holzner, Alon Ben-Arie, Léon C. Van Kempen, Edgar Petru, Stephan Jahn, Yvette P. Geels, Leon F. Massuger, Frédéric Amant, Stephan Polterauer, Elisa Lappi-Blanco, Johan Bulten, Alexandra Meuter, Staci Tanouye, Peter OppeltMonika Stroh-Weigert, Alexander Reinthaller, Andrea Mariani, Werner Hackl, Michael Netzer, Uwe Schirmer, Ignace Vergote, Peter Altevogt, Christian Marth, Mina Fogel

Research output: Contribution to journalArticle

120 Scopus citations

Abstract

Background Despite the excellent prognosis of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients experience recurrence and die from this disease. We analyzed the value of immunohistochemical L1CAM determination to predict clinical outcome.MethodsWe conducted a retrospective multicenter cohort study to determine expression of L1CAM by immunohistochemistry in 1021 endometrial cancer specimens. The Kaplan-Meier method and Cox proportional hazard model were applied for survival and multivariable analyses. A machine-learning approach was used to validate variables for predicting recurrence and death.ResultsOf 1021 included cancers, 17.7% were rated L1CAM-positive. Of these L1CAM-positive cancers, 51.4% recurred during follow-up compared with 2.9% L1CAM-negative cancers. Patients bearing L1CAM-positive cancers had poorer disease-free and overall survival (two-sided Log-rank P <. 001). Multivariable analyses revealed an increase in the likelihood of recurrence (hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28) and death (HR = 15.01; 95% CI = 9.28 to 24.26). In the L1CAM-negative cancers FIGO stage I subdivision, grading and risk assessment were irrelevant for predicting disease-free and overall survival. The prognostic relevance of these parameters was related strictly to L1CAM positivity. A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence (sensitivity = 0.74; specificity = 0.91) and death (sensitivity = 0.77; specificity = 0.89).ConclusionsTo our knowledge, L1CAM has been shown to be the best-ever published prognostic factor in FIGO stage I, type I endometrial cancers and shows clear superiority over the standardly used multifactor risk score. L1CAM expression in type I cancers indicates the need for adjuvant treatment. This adhesion molecule might serve as a treatment target for the fully humanized anti-L1CAM antibody currently under development for clinical use.

Original languageEnglish (US)
Pages (from-to)1142-1150
Number of pages9
JournalJournal of the National Cancer Institute
Volume105
Issue number15
DOIs
StatePublished - Aug 7 2013

Fingerprint Dive into the research topics of 'L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation'. Together they form a unique fingerprint.

  • Cite this

    Zeimet, A. G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Azim, S. A., Müller-Holzner, E., Ben-Arie, A., Van Kempen, L. C., Petru, E., Jahn, S., Geels, Y. P., Massuger, L. F., Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., ... Fogel, M. (2013). L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation. Journal of the National Cancer Institute, 105(15), 1142-1150. https://doi.org/10.1093/jnci/djt144